samedan logo
 
 
 
spacer
home > ebr > summer 2019 > the renaissance of microbial fermentation
PUBLICATIONS
European Biopharmaceutical Review

The Renaissance of Microbial Fermentation

Initially, many smaller biologic drug substances − including recombinant proteins and peptides − were produced via microbial fermentation. However, with the advent of cell culture systems, interest shifted to mammalian systems to produce larger proteins and antibodies. Now, the introduction of smaller, complex next-generation molecules, such as bioconjugates, antibody fragments, and other scaffolds, are once again driving interest in fermentation as an effective manufacturing platform.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

 You must be a member of the site to make a comment.
spacer
Dr Vladas Bumelis is the founder of Northway Biotechpharma and Chairman of the company’s Board of Directors and Advisory Board. He has extensive experience in the pharma and biotechnology industries, having previously served as General Manager of Teva Pharmaceutical Industries, Chairman of the Board for Biofa and Biotechna, and Chairman of the Board and General Manager of the Institute of Applied Enzymology in Lithuania. In 2004, Vladas received the Science Award of Lithuania in recognition of his achievements in the development and production of recombinant proteins. He has a PhD and MSc in chemistry, as well as a PhD in biotechnology, from Vilnius University, Lithuania.
spacer
Dr Vladas Bumelis
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

Envirotainer praises industry collaboration as it handles billionth vaccine

Stockholm, December 22, 2021: Envirotainer, the global market leader in secure cold-chain solutions for air transportation of pharmaceuticals, is calling for continued collaboration between pharmaceutical firms and the logistics industry.
More info >>

White Papers

Clinical Trials in Russia Orange Paper: Summary of Year 2013

Synergy Research Group

Russia remains a very popular geography for local, regional, and global pharmaceutical companies to conduct clinical trials. Sponsors mention the following reasons for conducting studies in Russia: 1. Fast patient enrollment due to the centralized medical infrastructure. 2. Nearly 100% patient retention 3. GCP trained and certified Investigative Sites generating high quality data 4. Low cost: Average per patient cost is 60% to 70% below US and European prices due to the low cost of Investigators and the high concentration of patients in therapeutically aligned medical centers
More info >>

 

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement